Bank of America
ABUS icon

Bank of America’s Arbutus Biopharma ABUS Stock Holding History

Bank of America’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.58M Sell
1,683,628
-149,076
-8% -$652K ﹤0.01% 3160
2025
Q4 		$8.82M Buy
1,832,704
+381,882
+26% +$1.72M ﹤0.01% 2948
2025
Q3 		$6.59M Buy
1,450,822
+253,167
+21% +$930K ﹤0.01% 3741
2025
Q2 		$3.7M Buy
1,197,655
+739,429
+161% +$2.46M ﹤0.01% 4187
2025
Q1 		$1.6M Buy
458,226
+96,922
+27% +$323K ﹤0.01% 4866
2024
Q4 		$1.18M Buy
361,304
+171,906
+91% +$632K ﹤0.01% 4882
2024
Q3 		$729K Buy
189,398
+106,121
+127% +$407K ﹤0.01% 5256
2024
Q2 		$257K Buy
83,277
+14,814
+22% +$44.4K ﹤0.01% 5751
2024
Q1 		$177K Sell
68,463
-23,488
-26% -$60.8K ﹤0.01% 5945
2023
Q4 		$230K Buy
91,951
+1,191
+1% +$2.33K ﹤0.01% 5999
2023
Q3 		$184K Sell
90,760
-20,762
-19% -$43.5K ﹤0.01% 5943
2023
Q2 		$257K Buy
111,522
+23,545
+27% +$61.3K ﹤0.01% 5666
2023
Q1 		$267K Buy
87,977
+13,701
+18% +$38.6K ﹤0.01% 5771
2022
Q4 		$173K Buy
74,276
+19,092
+35% +$45.7K ﹤0.01% 5990
2022
Q3 		$105K Buy
55,184
+16,728
+43% +$39.4K ﹤0.01% 6322
2022
Q2 		$104K Sell
38,456
-9,307
-19% -$23.8K ﹤0.01% 6443
2022
Q1 		$143K Sell
47,763
-659,334
-93% -$2.02M ﹤0.01% 6663
2021
Q4 		$2.75M Buy
707,097
+90,512
+15% +$352K ﹤0.01% 4243
2021
Q3 		$2.65M Buy
616,585
+269,201
+77% +$897K ﹤0.01% 4182
2021
Q2 		$1.05M Sell
347,384
-28,864
-8% -$89.4K ﹤0.01% 4860
2021
Q1 		$1.25M Buy
376,248
+371,214
+7,374% +$1.43M ﹤0.01% 4646
2020
Q4 		$18K Buy
5,034
+2,033
+68% +$7.12K ﹤0.01% 6608
2020
Q3 		$9K Sell
3,001
-51,598
-95% -$157K ﹤0.01% 6467
2020
Q2 		$99K Buy
54,599
+50
+0.1% +$82 ﹤0.01% 5676
2020
Q1 		$55K Buy
54,549
+45,422
+498% +$123K ﹤0.01% 5828
2019
Q4 		$25K Sell
9,127
-91,331
-91% -$148K ﹤0.01% 6445
2019
Q3 		$153K Sell
100,458
-47,035
-32% -$81K ﹤0.01% 5816
2019
Q2 		$306K Buy
147,493
+137,990
+1,452% +$353K ﹤0.01% 5392
2019
Q1 		$34K Sell
9,503
-19,857
-68% -$76.2K ﹤0.01% 6336
2018
Q4 		$113K Buy
29,360
+1,098
+4% +$5.41K ﹤0.01% 5845
2018
Q3 		$267K Buy
28,262
+19,413
+219% +$193K ﹤0.01% 5321
2018
Q2 		$65K Buy
8,849
+5,734
+184% +$34.1K ﹤0.01% 6001
2018
Q1 		$16K Sell
3,115
-8,429
-73% -$44.6K ﹤0.01% 6452
2017
Q4 		$58K Buy
11,544
+9,594
+492% +$56.2K ﹤0.01% 6001
2017
Q3 		$12K Hold
1,950
– – ﹤0.01% 6467
2017
Q2 		$7K Hold
1,950
– – ﹤0.01% 6512
2017
Q1 		$6K Sell
1,950
-500
-20% -$1.39K ﹤0.01% 6630
2016
Q4 		$6K Buy
2,450
+500
+26% +$1.46K ﹤0.01% 6657
2016
Q3 		$7K Buy
1,950
+100
+5% +$391 ﹤0.01% 6482
2016
Q2 		$6K Hold
1,850
– – ﹤0.01% 6615
2016
Q1 		$8K Sell
1,850
-31,019
-94% -$111K ﹤0.01% 6439
2015
Q4 		$146K Sell
32,869
-200
-0.6% -$1.1K ﹤0.01% 5555
2015
Q3 		$201K Buy
33,069
+5,895
+22% +$52.3K ﹤0.01% 5334
2015
Q2 		$322K Buy
27,174
+27,058
+23,326% +$412K ﹤0.01% 4999
2015
Q1 		$2K Sell
116
-284
-71% -$5.82K ﹤0.01% 6682
2014
Q4 		$6K Buy
400
+100
+33% +$1.73K ﹤0.01% 7213
2014
Q3 		$6K Sell
300
-12,430
-98% -$203K ﹤0.01% 7488
2014
Q2 		$166K Buy
12,730
+12,230
+2,446% +$173K ﹤0.01% 5716
2014
Q1 		$11K Buy
+500
New +$8.98K ﹤0.01% 7160

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Bank of America's ABUS Position: Q1 2026 in Review

Bank of America reduced its Arbutus Biopharma (ABUS) stake by 8.1% in Q1 2026, selling an estimated $652K and leaving 1,683,628 shares worth $7.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3160.

Bank of America first reported a position in ABUS in Q1 2014 and has held it in 49 quarters since. The position peaked at $8.82M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Bank of America held 1,683,628 shares of Arbutus Biopharma worth $7.58M as of Q1 2026.
  • Bank of America sold 149,076 Arbutus Biopharma shares in Q1 2026, an estimated $652K.
  • Arbutus Biopharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3160 holding.
  • Bank of America first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 49 quarters since.
  • Bank of America's Arbutus Biopharma position peaked at $8.82M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.